Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson’s Disease Patients with Cognitive Deficits: A Meta-Analysis

Abstract EN

Objectives.

To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson’s disease (PD).

Methods.

Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included.

Effect sizes (Cohen’s d), the standardized mean difference in the scores of each cognitive domain, were compared using a random-effects model (MetaXL version 5.3).

Results.

Three studies were included in the final analysis.

For a change in complex attention in PD with mild cognitive impairment (MCI), the estimated effect size was small and nonsignificant (0.16 (95% CI: −0.09, 0.42), n = 42).

For changes in executive function, perceptual-motor function, language, social cognition, and learning and memory, the estimated effect sizes were small and medium, but nonsignificant.

A deteriorative trend in executive function was observed after atomoxetine treatment in PD with MCI.

For a change in global cognitive function in PD without MCI, the estimated effect size was large and significant.

Conclusion.

In idiopathic PD with MCI, atomoxetine does not improve complex attention.

Also, a deteriorative trend in the executive function was noted.